ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XGN Exagen Inc

1.4121
0.0021 (0.15%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Exagen Inc NASDAQ:XGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0021 0.15% 1.4121 1.40 1.51 1.4128 1.38 1.41 3,601 05:00:11

Exagen to Present at Cowen and Company 40th Annual Healthcare Conference

18/02/2020 1:25pm

GlobeNewswire Inc.


Exagen (NASDAQ:XGN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Exagen Charts.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, 2020 in Boston.  Mr. Rocca’s presentation will take place at 3:30 p.m. EST. 

A link to the live webcast of the presentation will be available online from the investor relations section of the Exagen website at https://investors.exagen.com/

A replay of the webcast will be accessible on the Exagen investor relations website beginning approximately one hour following the completion of the event.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on its proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

InvestorsWestwicke Partners Mike CavanaughMike.Cavanaugh@westwicke.com646.677.1838 Company ContactExagen Inc. Kamal Adawi, Chief Financial OfficerKAdawi@exagen.com760.477.5514

 

1 Year Exagen Chart

1 Year Exagen Chart

1 Month Exagen Chart

1 Month Exagen Chart

Your Recent History

Delayed Upgrade Clock